Prolastin 1000 mg

DRUG3 trials

Sponsors

Medizinische Universitaet Innsbruck, Grifols S.A., Fondazione IRCCS Policlinico San Matteo

Conditions

Alcohol-Associated HepatitisChronic Obstructive Pulmonary DiseaseSevere Alpha-1 Antitrypsin Deficiency (AATD)

Phase 2

Effect of Alpha-1 Antitrypsin Supplementation in Alcohol-Associated Hepatitis-A prospective Pilot Study

RecruitingCTIS2024-515794-99-00

Medizinische Universitaet InnsbruckAlcohol-Associated Hepatitis

Start: 2025-06-18Target: 16Updated: 2025-01-15

A two-center, randomized, double-blind, placebo-controlled study of intravenous plasma-purified alpha-1 antitrypsin for hospitalized patients with COPD exacerbations (AECOPD study)

RecruitingCTIS2024-517613-33-00

Fondazione IRCCS Policlinico San MatteoChronic Obstructive Pulmonary Disease

Start: 2025-10-16Target: 36Updated: 2025-10-13

Phase 3

Safety and clinical parameter assessment of a 12-week home self-infusion therapy with Prolastin® in patients with severe alpha-1-antitrypsin (AATD) deficiency. The “Sunshine Study”

RecruitingCTIS2024-515894-80-00

Grifols S.A.Severe Alpha-1 Antitrypsin Deficiency (AATD)

Start: 2025-07-01Target: 33Updated: 2025-08-26